Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
BeOne Medicines
Boehringer Ingelheim
National Institutes of Health Clinical Center (CC)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
Bristol-Myers Squibb
Seagen Inc.
Genmab
Seagen Inc.
PrECOG, LLC.
Merck Sharp & Dohme LLC
AstraZeneca
AstraZeneca
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Mirati Therapeutics Inc.
Hoosier Cancer Research Network
Eli Lilly and Company
Hoffmann-La Roche
AstraZeneca
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Incyte Corporation
Charite University, Berlin, Germany
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
AstraZeneca
Qilu Pharmaceutical Co., Ltd.
Hoffmann-La Roche
Akeso
AstraZeneca
Alliance for Clinical Trials in Oncology
AstraZeneca
AstraZeneca
Bayer
AbbVie